AAPL341.32+1.24 (+0.36%) ▲|ABBV266.20+3.00 (+1.14%) ▲|ABT109.56+2.29 (+2.13%) ▲|ACN171.48+6.82 (+4.14%) ▲|ADBE258.88+9.70 (+3.89%) ▲|AMAT451.28-25.18 (-5.28%) ▼|AMD432.93-21.69 (-4.77%) ▼|AMGN395.09+1.99 (+0.51%) ▲|AMT175.97+4.47 (+2.61%) ▲|AMZN227.71-3.15 (-1.36%) ▼|AVGO375.10-5.82 (-1.53%) ▼|AXP333.82-2.81 (-0.83%) ▼|BA212.31-9.26 (-4.18%) ▼|BAC61.89-0.74 (-1.17%) ▼|BKNG200.00+0.69 (+0.35%) ▲|BLK1,101.76+4.21 (+0.38%) ▲|BMY63.65+0.05 (+0.08%) ▲|BNY154.89-1.60 (-1.02%) ▼|BRK-B510.00-2.37 (-0.46%) ▼|C128.77-3.70 (-2.79%) ▼|CAT803.28-37.57 (-4.47%) ▼|CL92.19-0.54 (-0.58%) ▼|CMCSA24.44+0.25 (+1.03%) ▲|COF211.67-0.74 (-0.35%) ▼|COP118.37+4.27 (+3.74%) ▲|COST973.24+6.66 (+0.69%) ▲|CRM183.83+2.33 (+1.28%) ▲|CSCO116.35+0.77 (+0.66%) ▲|CVS108.31-1.03 (-0.94%) ▼|CVX192.55+4.97 (+2.65%) ▲|DE620.23-19.62 (-3.07%) ▼|DHR201.84+2.79 (+1.40%) ▲|DIS98.92+0.03 (+0.03%) ▲|DUK130.08+0.84 (+0.65%) ▲|EMR148.48-3.33 (-2.19%) ▼|FDX310.13-2.51 (-0.80%) ▼|GD393.38+0.19 (+0.05%) ▲|GE356.32-7.28 (-2.00%) ▼|GEV923.17-20.21 (-2.14%) ▼|GILD133.38-0.94 (-0.70%) ▼|GM91.00+0.70 (+0.77%) ▲|GOOG331.19-1.41 (-0.42%) ▼|GOOGL332.34-1.37 (-0.41%) ▼|GS990.92-42.42 (-4.11%) ▼|HD338.33-6.14 (-1.78%) ▼|HON242.76-4.30 (-1.74%) ▼|IBM227.34-0.22 (-0.09%) ▼|INTC83.85-2.45 (-2.84%) ▼|INTU326.39+13.40 (+4.28%) ▲|ISRG356.63-5.17 (-1.43%) ▼|JNJ268.16+1.43 (+0.54%) ▲|JPM350.20-7.12 (-1.99%) ▼|KO90.72+2.45 (+2.78%) ▲|LIN509.84-1.34 (-0.26%) ▼|LLY1,223.45+2.79 (+0.23%) ▲|LMT578.65-2.66 (-0.46%) ▼|LOW216.07-2.18 (-1.00%) ▼|LRCX258.03-11.58 (-4.30%) ▼|MA564.48+1.73 (+0.31%) ▲|MCD271.71-1.31 (-0.48%) ▼|MDLZ65.59+3.11 (+4.98%) ▲|MDT87.80+0.92 (+1.06%) ▲|META586.87-6.54 (-1.10%) ▼|MMM181.61-0.88 (-0.48%) ▼|MO75.43+0.61 (+0.82%) ▲|MRK130.75-1.07 (-0.81%) ▼|MS205.87-5.71 (-2.70%) ▼|MSFT392.47-0.89 (-0.23%) ▼|MU788.34-32.19 (-3.92%) ▼|NEE89.79+0.51 (+0.57%) ▲|NFLX72.02-0.38 (-0.52%) ▼|NKE42.55-0.50 (-1.16%) ▼|NOW113.16+2.54 (+2.30%) ▲|NVDA191.44-5.57 (-2.83%) ▼|ORCL117.86-2.10 (-1.75%) ▼|PEP145.02+2.16 (+1.51%) ▲|PFE25.22-0.03 (-0.12%) ▼|PG145.28-3.61 (-2.42%) ▼|PLTR123.59+0.06 (+0.05%) ▲|PM201.15+0.98 (+0.49%) ▲|QCOM159.03-3.85 (-2.36%) ▼|RTX217.66-0.92 (-0.42%) ▼|SBUX103.59+0.49 (+0.48%) ▲|SCHW105.77-0.20 (-0.19%) ▼|SO97.13+0.35 (+0.36%) ▲|SPG237.22+0.52 (+0.22%) ▲|T24.51-0.15 (-0.61%) ▼|TMO583.43+7.02 (+1.22%) ▲|TMUS181.76-0.63 (-0.35%) ▼|TSLA303.21-4.23 (-1.38%) ▼|TXN271.38-5.69 (-2.05%) ▼|UBER69.78-0.96 (-1.36%) ▼|UNH425.23-3.56 (-0.83%) ▼|UNP292.38-2.07 (-0.70%) ▼|UPS104.47-1.06 (-1.00%) ▼|USB63.56-0.88 (-1.36%) ▼|V369.53+2.94 (+0.80%) ▲|VZ48.16-0.04 (-0.07%) ▼|WFC85.13-1.74 (-2.00%) ▼|WMT113.21+0.11 (+0.10%) ▲|XOM158.57+5.53 (+3.61%) ▲|AAPL341.32+1.24 (+0.36%) ▲|ABBV266.20+3.00 (+1.14%) ▲|ABT109.56+2.29 (+2.13%) ▲|ACN171.48+6.82 (+4.14%) ▲|ADBE258.88+9.70 (+3.89%) ▲|AMAT451.28-25.18 (-5.28%) ▼|AMD432.93-21.69 (-4.77%) ▼|AMGN395.09+1.99 (+0.51%) ▲|AMT175.97+4.47 (+2.61%) ▲|AMZN227.71-3.15 (-1.36%) ▼|AVGO375.10-5.82 (-1.53%) ▼|AXP333.82-2.81 (-0.83%) ▼|BA212.31-9.26 (-4.18%) ▼|BAC61.89-0.74 (-1.17%) ▼|BKNG200.00+0.69 (+0.35%) ▲|BLK1,101.76+4.21 (+0.38%) ▲|BMY63.65+0.05 (+0.08%) ▲|BNY154.89-1.60 (-1.02%) ▼|BRK-B510.00-2.37 (-0.46%) ▼|C128.77-3.70 (-2.79%) ▼|CAT803.28-37.57 (-4.47%) ▼|CL92.19-0.54 (-0.58%) ▼|CMCSA24.44+0.25 (+1.03%) ▲|COF211.67-0.74 (-0.35%) ▼|COP118.37+4.27 (+3.74%) ▲|COST973.24+6.66 (+0.69%) ▲|CRM183.83+2.33 (+1.28%) ▲|CSCO116.35+0.77 (+0.66%) ▲|CVS108.31-1.03 (-0.94%) ▼|CVX192.55+4.97 (+2.65%) ▲|DE620.23-19.62 (-3.07%) ▼|DHR201.84+2.79 (+1.40%) ▲|DIS98.92+0.03 (+0.03%) ▲|DUK130.08+0.84 (+0.65%) ▲|EMR148.48-3.33 (-2.19%) ▼|FDX310.13-2.51 (-0.80%) ▼|GD393.38+0.19 (+0.05%) ▲|GE356.32-7.28 (-2.00%) ▼|GEV923.17-20.21 (-2.14%) ▼|GILD133.38-0.94 (-0.70%) ▼|GM91.00+0.70 (+0.77%) ▲|GOOG331.19-1.41 (-0.42%) ▼|GOOGL332.34-1.37 (-0.41%) ▼|GS990.92-42.42 (-4.11%) ▼|HD338.33-6.14 (-1.78%) ▼|HON242.76-4.30 (-1.74%) ▼|IBM227.34-0.22 (-0.09%) ▼|INTC83.85-2.45 (-2.84%) ▼|INTU326.39+13.40 (+4.28%) ▲|ISRG356.63-5.17 (-1.43%) ▼|JNJ268.16+1.43 (+0.54%) ▲|JPM350.20-7.12 (-1.99%) ▼|KO90.72+2.45 (+2.78%) ▲|LIN509.84-1.34 (-0.26%) ▼|LLY1,223.45+2.79 (+0.23%) ▲|LMT578.65-2.66 (-0.46%) ▼|LOW216.07-2.18 (-1.00%) ▼|LRCX258.03-11.58 (-4.30%) ▼|MA564.48+1.73 (+0.31%) ▲|MCD271.71-1.31 (-0.48%) ▼|MDLZ65.59+3.11 (+4.98%) ▲|MDT87.80+0.92 (+1.06%) ▲|META586.87-6.54 (-1.10%) ▼|MMM181.61-0.88 (-0.48%) ▼|MO75.43+0.61 (+0.82%) ▲|MRK130.75-1.07 (-0.81%) ▼|MS205.87-5.71 (-2.70%) ▼|MSFT392.47-0.89 (-0.23%) ▼|MU788.34-32.19 (-3.92%) ▼|NEE89.79+0.51 (+0.57%) ▲|NFLX72.02-0.38 (-0.52%) ▼|NKE42.55-0.50 (-1.16%) ▼|NOW113.16+2.54 (+2.30%) ▲|NVDA191.44-5.57 (-2.83%) ▼|ORCL117.86-2.10 (-1.75%) ▼|PEP145.02+2.16 (+1.51%) ▲|PFE25.22-0.03 (-0.12%) ▼|PG145.28-3.61 (-2.42%) ▼|PLTR123.59+0.06 (+0.05%) ▲|PM201.15+0.98 (+0.49%) ▲|QCOM159.03-3.85 (-2.36%) ▼|RTX217.66-0.92 (-0.42%) ▼|SBUX103.59+0.49 (+0.48%) ▲|SCHW105.77-0.20 (-0.19%) ▼|SO97.13+0.35 (+0.36%) ▲|SPG237.22+0.52 (+0.22%) ▲|T24.51-0.15 (-0.61%) ▼|TMO583.43+7.02 (+1.22%) ▲|TMUS181.76-0.63 (-0.35%) ▼|TSLA303.21-4.23 (-1.38%) ▼|TXN271.38-5.69 (-2.05%) ▼|UBER69.78-0.96 (-1.36%) ▼|UNH425.23-3.56 (-0.83%) ▼|UNP292.38-2.07 (-0.70%) ▼|UPS104.47-1.06 (-1.00%) ▼|USB63.56-0.88 (-1.36%) ▼|V369.53+2.94 (+0.80%) ▲|VZ48.16-0.04 (-0.07%) ▼|WFC85.13-1.74 (-2.00%) ▼|WMT113.21+0.11 (+0.10%) ▲|XOM158.57+5.53 (+3.61%) ▲|
21.2 C
New York
Wednesday, July 29, 2026

Tag: red blood cell

newssourceFORcompanyinformationcontent1releasesmarket

Vascarta Announces Phase I Results of VAS-101 Administered Sublingually in Sickle Cell Disease Patients

SUMMIT, N.J., June 24, 2026 /PRNewswire/ -- Vascarta Inc., a clinical-stage biopharmaceutical company advancing innovative treatments for pain and inflammation, announced today the successful...

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

BEERSE, BELGIUM, June 13, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced results from the investigational Phase 3 MonumenTAL-3 study.1 The results showed that TALVEY® (talquetamab), a GPRC5D bispecific antibody, in combination with daratumumab with or without pomalidomide demonstrated significant reduction in the risk of disease progression or death of up to 72.0%, and clinically meaningful reduction of up to 53.0% in the risk of death, compared to the standard regimen of daratumumab, pomalidomide, and dexamethasone (DPd) in patients with relapsed or refractory multiple myeloma (RRMM).1 Results showed a progression-free survival (PFS) rate of up to 81.3% versus standard of care (51.2%) and an overall survival (OS) rate of up to 89.2% versus standard of care (79.1%) at 24 months.1  

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

TALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 monthsMonumenTAL-3 is the...

HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress

— Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile —

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven...

Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglobin responseb, with mean hemoglobin improvement of at least 1 g/dL as...

Sciaticyl’s “Nerve Reset” Discovery Sparks 2025 Surge in Sciatica Support Solutions Across U.S.

A powerful surge in online searches for natural sciatica remedies has thrust Sciaticyl into the spotlight, thanks to a peculiar “nerve reset” approach linked to ancient herbal wisdom and modern neuroscience. This unique formulation blends 11 ingredients—including Bacopa Monnieri, Alpha Lipoic Acid, and key nerve-regenerating compounds—positioning Sciaticyl as a leading curiosity point for those seeking non-surgical options. As nerve pain awareness grows in 2025, researchers and consumers alike are exploring how nutritional support may play a role in long-term sciatica recovery, vitality, and freedom from discomfort. 
A powerful surge in online searches for natural sciatica remedies has thrust Sciaticyl into the spotlight, thanks to a peculiar “nerve reset” approach linked to ancient herbal wisdom and modern neuroscience. This unique formulation blends 11 ingredients—including Bacopa Monnieri, Alpha Lipoic Acid, and key nerve-regenerating compounds—positioning Sciaticyl as a leading curiosity point for those seeking non-surgical options. As nerve pain awareness grows in 2025, researchers and consumers alike are exploring how nutritional support may play a role in long-term sciatica recovery, vitality, and freedom from discomfort.

Muscle Building Supplements 2025: CrazyBulk Introduces Effective Bodybuilding Supplements For Muscle Growth, Bulking, Cutting And Strength in USA

Muscle Building Supplements: A Game-Changer in Strength Training Programs 
Muscle Building Supplements: A Game-Changer in Strength Training Programs

Safi Biotherapeutics and Functional Fluidics Initiate Collaboration to Validate Health and Quality of Manufactured RBCs

Collaboration to support Safi IND data package for use of mRBCs in sickle cell disease chronic transfusions CAMBRIDGE, Mass. and DETROIT, July 16, 2025 /PRNewswire/...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsRed blood cell

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers